Pharma Solutions by Dr. Ajay

  Medications for acid reflux, heartburn, and GERD (gastroesophageal reflux disease) come in three types: H2 blockers, proton pump inhibitors (PPIs), and antacids. They all work differently and are geared towards either prevention or quick relief. H2 blockers and proton pump inhibitors work better than antacids, but if you need something for very quick relief, antacids are an option. Antacids don’t do anything to prevent GERD (gastroesophageal reflux disease), but they can be used on demand for symptom relief. They are cheap and available over the counter.H2 blockers (histamine blockers) block one of the first stimuli for  acid production.  PPIs block the final step in the pathway of  acid secretion  in the stomach. In other words, the acid which has been produced (which may be reduced due to an H2 blocker) is prevented from arriving in the stomach. Of the three classes, antacids are the fastest acting. They start providing relief to the patient within five minutes. The Global Market i

  Introduction: Poorly soluble drugs are a major issue for the pharmaceutical industry. By using solubility enhancement excipients pharmaceutical formulators can increase the bioavailability of the API. Advanced solubility enhancement excipients can help companies bring products to market faster. Nowadays most of the drug substances are coming into the innovation pipeline with poor water solubility. Here, the influence of excipients will play a significant role to improve the dissolution of poorly aqueous soluble compounds. The drug substance needs to be dissolved in gastric fluids to get the better absorption and bioavailability of an orally administered drug. Dissolution is the rate-controlling stage for drugs which controls the rate and degree of absorption. Usually, poorly soluble oral administrated drugs show a slower dissolution rate, inconsistent and incomplete absorption which can lead to lower bioavailability. The low aqueous solubility of BCS class II and IV drugs is a major

Introduction: Presently pharmaceutical industries are focusing on development of sustained release formulations due to its inherent boons. Sustained release dosage forms are designed to release a drug at a predetermined rate by maintaining a constant drug level for a specific period of time. The basic rationale of sustained release drug delivery system optimizes the biopharmaceutical, pharmacokinetic and pharmacodynamics properties of a drug in such a way that its utility is maximized, side-effects are reduced and cure of the disease is achieved. Sustained release (SR) preparations are not new but several new modifications are being introduced. Rising number of patent expirations and soaring need for pediatric and geriatric dosage forms are providing a boost to the growth of the market. Growing awareness regarding added benefits provided by sustained release formulations is also stimulating the growth of the market.   SR has received most of the attention because of the fact that the

  Solid oral dosage forms are most acceptable dosage forms especially tablets are most widely accepted by people of different age groups. A multifunctional and multiple unit system for oral use are developed by filling versatile mini tablets in a capsule. It is a multifunctional and multiple unit system for oral use and can be developed by filling versatile tablets in a capsule, for example: Immediate release mini tablets, Rapid-release Mini-Tablets (RMTs), Sustained release Mini-Tablets (SMTs), Pulsatile Mini-Tablets (PMTs), and Delayed-onset Sustained release Mini-Tablets (DSMTs). In this technology we can reduce the size of the tablet such that it could be enclosed in a capsule, and then deployed within one single dosage form. Mini tablets are multiple unit dosage forms and are advantageous than pellets or any other oral dosage forms as they are easy to manufacture, and stability problems are less. The oral controlled release drug delivery system included two types of dosage forms: